Prospective study of regular aspirin use and the risk of breast cancer
Prospective study of regular aspirin use and the risk of breast cancer
复制标题
DOI：
10.1093/jnci/88.14.988
复制
发表时间：
1996-07-17
期刊：
影响因子：
--
通讯作者：
Colditz, GA
中科院分区：
文献类型：
--
作者：
Egan, KM;Stampfer, MJ;Colditz, GA
背景：有证据表明阿司匹林和其他非甾体抗炎药（NSAIDs）可以抑制大肠肿瘤的发展。已经观察到非甾体抗炎药的使用与乳腺癌的发病率之间存在负相关，但在所有研究中，这种相关性并不具有统计学意义。目的：我们分析了前瞻性护士健康研究的数据，以评估阿司匹林使用对乳腺癌风险的影响。方法：我们研究了89528名女性注册护士，她们没有乳腺癌或其他癌症病史（不包括非黑色素瘤皮肤癌），并于1980年返回了一份邮寄的问卷，该问卷调查了有关乳腺癌风险因素以及当前和过去阿司匹林使用情况的信息。每两年向参与者邮寄一次随访问卷;这些妇女被随访到1992年。从每两年一次的调查问卷中获得有关阿司匹林当前使用情况的信息，但1986年除外，通过调查问卷回答确定了乳腺癌病例，并寻求审查医疗记录以确认诊断的许可，我们的分析基于2414例浸润性乳腺癌病例，包括2303例有病历证实的病例和111例无病历证实的病例，相对风险（RR）和95%置信区间（CI），针对年龄或年龄加上其它已知或潜在的乳腺癌风险因素进行调整（即，结果：1980年规律服用阿司匹林（每周2片或2片以上）与随后12年的乳腺癌发病率无关（以不规律服用阿司匹林为参照，多变量RR = 1.03，95% CI = 0.95-1.12）。在1980年至1988年期间，持续定期使用阿司匹林的相应风险估计值为1.01（95% CI = 0.80-1.27），大量使用阿司匹林的风险相似（每天超过两片[即，>14/周]，多变量RR [95%CI]分别为1.05 [0.89-1.23]和1.09 [0.75-1.60]）和长期定期使用（例如，20年或更长时间的规律使用，多变量RR = 1.00; 95%CI = 0.71-1.41），结论：我们的研究结果表明，规律使用阿司匹林并不能降低乳腺癌的风险。
Background: Evidence suggests that aspirin and other nonsteroidal anti-inflammmatory drugs (NSAIDs) can inhibit tumor development in the large bowel. An inverse association between the use of NSAIDs and the incidence of breast cancer has been observed, but this association has not been statistically significant in all studies, Purpose: We analyzed data from the prospective Nurses' Health Study to evaluate the influence of aspirin use on breast cancer risk, Methods: We studied a population of 89 528 female registered nurses who reported no history of breast or other cancers (excluding nonmelanoma skin cancer) and who returned a mailed questionnaire in 1980 that elicited information concerning breast cancer risk factors and current and past aspirin use. Follow-up questionnaires were mailed to the participants every 2 years; the women were followed through 1992. Information concerning current aspirin use was obtained from each biennial questionnaire, except in 1986, Cases of breast cancer were identified through questionnaire responses, and permission was sought for a review of medical records to confirm the diagnoses, Our analysis was based on 2414 cases of invasive breast cancer, which included 2303 cases confirmed with medical records and 111 cases for which no records were obtained, Relative risks (RRs) with 95% confidence intervals (CIs), adjusted for age or age plus other known or potential breast cancer risk factors (i.e., multivariate), were calculated, Results: Regular aspirin use (two or more tablets per week) in 1980 was unrelated to breast cancer incidence during the succeeding 12-year period (with no regular aspirin use as the referent, multivariate RR = 1.03; 95% CI = 0.95-1.12). The corresponding risk estimate for consistent regular aspirin use during the period from 1980 through 1988 was 1.01 (95% CI = 0.80-1.27), The risks were similar for heavy aspirin use (for more than two tablets per day [i.e., >14 per week] in 1980 and in 1980 through 1988, the multivariate RRs [95% CIs] were 1.05 [0.89-1.23] and 1.09 [0.75-1.60], respectively) and for extended durations of regular use (e.g., for 20 years or more of regular use, multivariate RR = 1.00; 95% CI = 0.71-1.41), Conclusion: Our results indicate that regular aspirin use does not reduce the risk of breast cancer.